Last updated: February 17, 2026
Development Overview
Rapastinel (formerly GLYX-13), developed by Allogene Therapeutics in partnership with Allergan, is a glyoxalase 1 (GLO1) pathway modulator examined primarily for treatment-resistant depression (TRD). It functions as a partial agonist at the NMDA receptor, aiming to provide rapid antidepressant effects without the side effects associated with ketamine.
Clinical Trials and Regulatory Milestones
-
Phase 2 trials demonstrated significant antidepressant effects after a 2-week treatment period in patients with TRD. The trials included around 400 participants across multiple sites.
-
A Phase 3 trial was initiated but was put on hold in 2020 due to strategic reprioritization and evolving data, with no subsequent updates confirming termination or resumption.
-
The FDA granted Fast Track designation in 2018 for depression, aiming to expedite development and review processes.
Current Development Status (2023)
- No active Phase 3 or late-phase trials are publicly registered or underway.
- The developer has shifted focus toward biomarkers and mechanistic studies, possibly in anticipation of future clinical development.
- Funding has notably decreased, with no recent capital raises or licensing deals announced for Rapastinel.
Market Projection
Depression Treatment Market
- Global depression treatment market was valued at estimated USD 11.5 billion in 2022 and is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 2.5% through 2030[1].
- The shift toward rapid-acting antidepressants (RAADs) has increased interest in NMDA receptor modulators like Rapastinel, ketamine, and esketamine.
Competitive Landscape
| Drug Candidate |
Approval Status |
Mechanism |
Marketed Products |
Notes |
| Esketamine (Spravato) |
Approved 2019 |
NMDA receptor antagonist |
Esketamine nasal spray |
First rapid-acting FDA-approved antidepressant in this class. |
| Ketamine |
Off-label use |
NMDA receptor antagonist |
N/A |
Used off-label; requires monitoring. |
| Rapastinel |
Clinical development |
NMDA receptor partial agonist |
None |
Phase 2 completed; no late-stage data. |
Market Challenges and Opportunities
- Challenges: Uncertain regulatory pathway following Phase 2, competition from existing RAADs, and limited clinical data.
- Opportunities: Growing acceptance of rapid-acting therapies, potential for a better side effect profile, and expansion into other neuropsychiatric indications (e.g., post-traumatic stress disorder, anxiety).
Economic Considerations
- The cost of clinical development for neuropsychiatric drugs exceeds USD 1 billion, factoring in clinical trials, regulatory fees, and post-approval research[2].
- The absence of recent licensing or partnership agreements suggests limited near-term commercial prospects unless new clinical data emerge.
Strategic Outlook
- Unless new evidence supports resumed development, Rapastinel's commercial potential remains speculative.
- Focus may shift to biomarker validation or novel indications where it can fill unmet needs.
- Alternative approaches include licensing to or acquisition by companies with existing infrastructure for rapid-acting antidepressants.
Key Takeaways
- Rapastinel has completed Phase 2 research but is currently inactive, with no announced plans for Phase 3 or commercialization.
- The depression treatment market continues to favor drugs with rapid onset and improved safety profiles.
- The competitive environment is dense, with approved drugs like Esketamine setting high standards for safety and efficacy.
- Future success hinges on additional clinical data, strategic partnerships, or repositioning within neuropsychiatric disorders.
Frequently Asked Questions (FAQs)
-
What was the primary benefit of Rapastinel in clinical trials?
It demonstrated rapid antidepressant effects in patients with treatment-resistant depression, with fewer side effects compared to ketamine.
-
Why did development of Rapastinel stall?
The sponsor shifted focus away from late-stage development after mixed results in Phase 2 and strategic reconsideration, with no recent activity reported.
-
Are there any ongoing trials for Rapastinel?
As of 2023, no active clinical trials are publicly registered or confirmed.
-
Could Rapastinel still enter the market?
Its commercial prospects are limited unless new clinical data indicate sufficient efficacy and safety to restart development or attract licensing partners.
-
How does Rapastinel compare to approved treatments like Esketamine?
Rapastinel was designed to offer rapid antidepressant effects with a potentially better safety profile, but it has not achieved regulatory approval or market presence.
References
[1] Grand View Research, "Depression Treatment Market Size," 2022.
[2] DiMasi, J., et al. "The Cost of Innovation in the Pharmaceutical Industry," Journal of Health Economics, 2016.
Note: All data is current as of 2023. Further updates may alter the development status.
